1. Home
  2. PEBK vs IKT Comparison

PEBK vs IKT Comparison

Compare PEBK & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Peoples Bancorp of North Carolina Inc.

PEBK

Peoples Bancorp of North Carolina Inc.

HOLD

Current Price

$43.76

Market Cap

232.7M

Sector

Finance

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.61

Market Cap

274.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PEBK
IKT
Founded
1912
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.7M
274.9M
IPO Year
2012
2020

Fundamental Metrics

Financial Performance
Metric
PEBK
IKT
Price
$43.76
$1.61
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
★ $5.55
AVG Volume (30 Days)
20.6K
★ 628.3K
Earning Date
10-19-2026
11-13-2026
Dividend Yield
★ 1.92%
N/A
EPS Growth
21.48
★ 57.76
EPS
★ 1.76
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$33.33
P/E Ratio
$24.95
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$27.33
$1.33
52 Week High
$45.78
$2.61

Technical Indicators

Market Signals
Indicator
PEBK
IKT
Relative Strength Index (RSI) 48.91 32.05
Support Level $41.70 $1.58
Resistance Level $45.38 $1.74
Average True Range (ATR) 1.04 0.12
MACD -0.05 -0.01
Stochastic Oscillator 50.09 19.59

Price Performance

Historical Comparison
PEBK
IKT

About PEBK Peoples Bancorp of North Carolina Inc.

Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: